News - 2 New Members Of Medical Advisory Board
NEW YORK--(BUSINESS WIRE)--Dec. 23, 1997--Chromatics Color Sciences International Inc. (NASDAQ:CCSI) is pleased to announce that two new members have joined the company's medical advisory board signing exclusive agreements with the company in the field of noninvasive Bilirubinometry.
The first new member, Dr. Ian Holzman, chief, division of newborn medicine at Mt. Sinai Hospital in New York City was also the principal investigator for the company's extensive clinical trials conducted at Mt. Sinai Hospital for the company's 510k submission on noninvasive monitoring of bilirubin jaundice.
The second new member, Dr. M. Jeffrey Maisels, chairman, dept. of pediatrics, William Beaumont Hospital, clinical professor of pediatrics, University of Michigan Medical School, is an internationally recognized medical expert in Bilirubin infant jaundice. Dr. Maisels has written extensively on bilirubin.
"We are fortunate indeed to have Dr. Maisels and Dr. Holzman's expert assistance in moving forward into global presentation to the medical community of our medical systems for noninvasive monitoring of Bilirubin...", said Darby Macfarlane, CEO of CCSI.
In other related news, the company announced today that of the warrants outstanding since the company received FDA clearance on July 30, 1997, 1,138,992 warrants have been exercised for $5 per share generating $5,694,960 in proceeds, and bringing the company's cash balance to $9,385,000 at Nov. 15, 1997.
The company is engaged in the business of color science..................
Certain of the matters discussed in this announcement contain forward-looking statements ............... |
